Hanley David C., an insider at Nuvation Bio Inc (NUVB), purchased 224,000 shares of the company at a price of $1.87 each on November 18, 2025. This transaction totaled $419,000, bringing Hanley's total holdings to 224,000 shares.
Nuvation Bio, a biopharmaceutical company based in San Francisco, focuses on addressing unmet needs in oncology through its innovative therapeutic candidates. The firm, which went public on July 1, 2020, has a market capitalization of $2.5 billion and reported an earnings per share (EPS) of -0.64 for the trailing twelve months.
The upcoming earnings report is anticipated on August 5, 2026, with an EPS estimate of -0.17 and revenue expected to reach $37.6 million.
Insider buying often signals confidence in a company's future prospects, as executives typically have access to critical, non-public information. However, investors are advised to consider these transactions within a broader context, examining patterns across multiple insiders and time periods rather than isolated events. Such decisions reflect the complexities behind insider trading and should be weighed alongside other fundamental and technical factors in the market.